AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31060571 — intervention group
Group type: EXPERIMENTAL
Intervention: Health services provided in municipalities
Number of subjects: 491
Study 31060571 — intervention group
Group type: EXPERIMENTAL
Intervention: Health services related to housing, economy, exercise, and social network
Number of subjects: 491
Study 31060571 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction with practical help
Number of subjects: 491
Study 31060571 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction with personnel
Number of subjects: 491
Study 31060571 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall satisfaction
Number of subjects: 491
Study 28558384 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg intravenous paracetamol
Number of subjects: 60
Study 28558384 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg intravenous paracetamol
Number of subjects: 60
Study 28558384 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/kg intravenous paracetamol
Number of subjects: 60
Study 28558384 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol (all doses combined)
Number of subjects: 60
Study 28558384 — intervention group
Group type: COMPARATOR
Intervention: Oral sucrose (control group)
Number of subjects: 60
Study 26075931 — intervention group
Group type: EXPERIMENTAL
Intervention: LESS-TLH
Number of subjects: 76
Study 26075931 — intervention group
Group type: COMPARATOR
Intervention: LESS-LAVH
Number of subjects: 76
Study 24617224 — intervention group
Group type: EXPERIMENTAL
Intervention: CT virtual endoscopy and pathological check
Number of subjects: 80
Study 24617224 — intervention group
Group type: COMPARATOR
Intervention: Conventional colonoscopy and pathological check
Number of subjects: 80
Study 20875216 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed oil (FXCO)
Number of subjects: 36
Study 20875216 — intervention group
Group type: EXPERIMENTAL
Intervention: High-oleic rapeseed oil (HOCO)
Number of subjects: 36
Study 20875216 — intervention group
Group type: COMPARATOR
Intervention: Western diet (WD)
Number of subjects: 36
Study 19134454 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbs for calming liver and suppressing liver-yang
Number of subjects: 32
Study 19134454 — intervention group
Group type: COMPARATOR
Intervention: Flunarizine Capsules
Number of subjects: 32
Study 16702322 — intervention group
Group type: EXPERIMENTAL
Intervention: High flavanol cocoa (326 mg/d)
Number of subjects: 2
Study 16702322 — intervention group
Group type: COMPARATOR
Intervention: Low flavanol cocoa (27 mg/d)
Number of subjects: 2
Study 15378354 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg tid) with conventional treatment
Number of subjects: 22
Study 15378354 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional treatment alone)
Number of subjects: 22
Study 12575970 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (225 mg/day) before treatment
Number of subjects: 8
Study 12575970 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (225 mg/day) after treatment
Number of subjects: 8
Study 12575970 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (0.154 mol/l at 8 ml/kg/h for 4 h) before captopril
Number of subjects: 8
Study 9605680 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural 0.5% bupivacaine followed by 0.25% bupivacaine
Number of subjects: 30
Study 9605680 — intervention group
Group type: COMPARATOR
Intervention: Control group (unwarmed)
Number of subjects: 30
Study 9605680 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 8583674 — intervention group
Group type: EXPERIMENTAL
Intervention: Portex catheter (Group A)
Number of subjects: 20
Study 8583674 — intervention group
Group type: COMPARATOR
Intervention: Arrow catheter (Group B)
Number of subjects: 20
Study 2677058 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronal Scaling (CS)
Number of subjects: 75
Study 2677058 — intervention group
Group type: EXPERIMENTAL
Intervention: Root Planning (RP)
Number of subjects: 75
Study 2677058 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Widman Surgery (MW)
Number of subjects: 75
Study 2677058 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap with Osseous Resectional Surgery (FO)
Number of subjects: 75
Study 629218 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation of 300 mg administered daily from the 20th week of gestation until term
Number of subjects: 87
Study 629218 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation of 600 mg administered daily from the 20th week of gestation until term
Number of subjects: 87
Study 629218 — intervention group
Group type: COMPARATOR
Intervention: Unsupplemented mothers
Number of subjects: 87
Study 30703137 — intervention group
Group type: EXPERIMENTAL
Intervention: Native language condition
Number of subjects: 500
Study 30703137 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching language condition
Number of subjects: 500
Study 30703137 — intervention group
Group type: EXPERIMENTAL
Intervention: Second language condition
Number of subjects: 500
Study 30703137 — intervention group
Group type: EXPERIMENTAL
Intervention: Low English proficiency
Number of subjects: 500
Study 30703137 — intervention group
Group type: COMPARATOR
Intervention: All groups (native, switching, second language)
Number of subjects: 500
Study 27878951 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-feedback intervention for positive parenting and learning difficulties (VIPP-LD)
Number of subjects: 85
Study 27878951 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual
Number of subjects: 85
Study 25675061 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (5 mcg) with 3 mL of 0.5% hyperbaric bupivacaine
Number of subjects: 60
Study 25675061 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (1 mg) with 3 mL of 0.5% hyperbaric bupivacaine
Number of subjects: 60
Study 25675061 — intervention group
Group type: COMPARATOR
Intervention: Control (0.5 mL of 0.9% saline) with 3 mL of 0.5% hyperbaric bupivacaine
Number of subjects: 60
Study 24098631 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive rhythmic cue
Number of subjects: 32
Study 24098631 — intervention group
Group type: COMPARATOR
Intervention: Fixed tempo cue
Number of subjects: 32
Study 24098631 — intervention group
Group type: COMPARATOR
Intervention: 1/f fluctuating tempo cue
Number of subjects: 32
Study 24098631 — intervention group
Group type: COMPARATOR
Intervention: No cue
Number of subjects: 32
Study 21843846 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring by phone and home visits using checklists
Number of subjects: 97
Study 21843846 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone monitoring
Number of subjects: 97
Study 21843846 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits
Number of subjects: 97
Study 19675462 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐addition silicone hydrogel multifocal soft lens
Number of subjects: 0
Study 19675462 — intervention group
Group type: COMPARATOR
Intervention: Monovision
Number of subjects: 0
Study 19675462 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal correction
Number of subjects: 0
Study 19675462 — intervention group
Group type: COMPARATOR
Intervention: Habitual correction
Number of subjects: 0
Study 19675462 — intervention group
Group type: COMPARATOR
Intervention: Optimized distance visual correction
Number of subjects: 0
Study 17920506 — intervention group
Group type: EXPERIMENTAL
Intervention: LED curing
Number of subjects: 30
Study 17920506 — intervention group
Group type: COMPARATOR
Intervention: Halogen light curing
Number of subjects: 30
Study 15477437 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac solution
Number of subjects: 326
Study 15477437 — intervention group
Group type: COMPARATOR
Intervention: Vehicle-control solution
Number of subjects: 326
Study 11252296 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ventricular catheter placement
Number of subjects: 77
Study 11252296 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventricular catheter placement
Number of subjects: 77
Study 11252296 — intervention group
Group type: COMPARATOR
Intervention: Comparison of endoscopic vs conventional placement
Number of subjects: 77
Study 9990211 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation (PCS) with propofol (bolus: 0.2 mg.kg‐1, lockout time: 3 min)
Number of subjects: 11
Study 9990211 — intervention group
Group type: COMPARATOR
Intervention: Anesthesiologist-controlled sedation (ACS) with propofol (continuous infusion)
Number of subjects: 11
Study 9990211 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PCS and ACS
Number of subjects: 11
Study 29663517 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective continuous glucose monitoring (CGM) (6-day sensor) at 28, 32 and 36 weeks' gestation, n = 25
Number of subjects: 50
Study 29663517 — intervention group
Group type: COMPARATOR
Intervention: Usual antenatal care without CGM, n = 25
Number of subjects: 50
Study 28064028 — intervention group
Group type: EXPERIMENTAL
Intervention: REAL Diabetes intervention
Number of subjects: 81
Study 28064028 — intervention group
Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 81
Study 25719754 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (100 mg)
Number of subjects: 15
Study 25719754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 23756425 — intervention group
Group type: EXPERIMENTAL
Intervention: Septilin® tablets for two weeks following scaling and root planing
Number of subjects: 40
Study 23756425 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing alone
Number of subjects: 40
Study 20058594 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg plus folic acid 0.4 mg daily (low-dose group)
Number of subjects: 273
Study 20058594 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg combined with folic acid 0.8 mg daily (high-dose group)
Number of subjects: 273
Study 20058594 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10 mg/d alone (control)
Number of subjects: 273
Study 17532073 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 41
Study 17532073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 15364767 — intervention group
Group type: EXPERIMENTAL
Intervention: E5531 (100 microg, 250 microg, 500 microg, or 1,000 microg)
Number of subjects: 32
Study 15364767 — intervention group
Group type: COMPARATOR
Intervention: LPS (4 ng/kg)
Number of subjects: 32
Study 12066939 — intervention group
Group type: EXPERIMENTAL
Intervention: Humidified oxygen (40% mixture)
Number of subjects: 32
Study 12066939 — intervention group
Group type: COMPARATOR
Intervention: Humidified air
Number of subjects: 32
Study 9594989 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and magnesium-rich mineral water
Number of subjects: 85
Study 9594989 — intervention group
Group type: COMPARATOR
Intervention: Mineral water deficient in calcium and magnesium
Number of subjects: 85
Study 9594989 — intervention group
Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 85
Study 7661123 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein (0.5 mumol/kg body wt)
Number of subjects: 8
Study 7661123 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene (0.5 mumol/kg body wt)
Number of subjects: 8
Study 7661123 — intervention group
Group type: COMPARATOR
Intervention: Combined doses of lutein and beta-carotene
Number of subjects: 8
Study 7661123 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein
Number of subjects: 8
Study 2759842 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal-therapist-contact cognitive-behavioral therapy
Number of subjects: 48
Study 2759842 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-based cognitive-behavioral therapy
Number of subjects: 48
Study 2759842 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 48
Study 370527 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 22
Study 370527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31366405 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-needle warm acupuncture
Number of subjects: 160
Study 31366405 — intervention group
Group type: COMPARATOR
Intervention: Stainless steel filiform-needle warm acupuncture
Number of subjects: 160
Study 28370730 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind-body techniques and health-promoting lifestyle modification (7-hour once-per-week group sessions over 12 weeks)
Number of subjects: 86
Study 28370730 — intervention group
Group type: COMPARATOR
Intervention: Waiting group (no intervention)
Number of subjects: 86
Study 28370730 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study population (after 6-month follow-up)
Number of subjects: 86
Study 26258571 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 32
Study 26258571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 26258571 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 32
Study 22230883 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral leucovorin calcium (2 mg/kg per day; maximum 50 mg per day)
Number of subjects: 93
Study 22230883 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 93
Study 21730977 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling of vaginal fluid (Qvintip) and HPV testing
Number of subjects: 4060
Study 21730977 — intervention group
Group type: COMPARATOR
Intervention: Pap-smear screening (control)
Number of subjects: 4060
Study 19539096 — intervention group
Group type: COMPARATOR
Intervention: SSRIs
Number of subjects: 18
Study 19539096 — intervention group
Group type: COMPARATOR
Intervention: TCAs
Number of subjects: 18
Study 19539096 — intervention group
Group type: COMPARATOR
Intervention: SNRIs (venlafaxine)
Number of subjects: 18
Study 19539096 — intervention group
Group type: COMPARATOR
Intervention: Duloxetine (SNRI)
Number of subjects: 18
Study 17688756 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 553
Study 17688756 — intervention group
Group type: COMPARATOR
Intervention: Orthopaedic specialist consultation
Number of subjects: 553
Study 15378676 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (34.1 mg daily)
Number of subjects: 100
Study 15378676 — intervention group
Group type: COMPARATOR
Intervention: Sertraline (101.5 mg daily)
Number of subjects: 100
Study 15378676 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 100
Study 15378676 — intervention group
Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 100
Study 11453895 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-fluticasone propionate (FP) 1000 microg
Number of subjects: 16
Study 11453895 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-beclomethasone dipropionate (BDP) 1000 microg
Number of subjects: 16
Study 11453895 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-beclomethasone dipropionate (BDP) 2000 microg
Number of subjects: 16
Study 11453895 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-fluticasone propionate (FP) 2000 microg
Number of subjects: 16
Study 11453895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9543964 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured education program (experimental group)
Number of subjects: 30
Study 9543964 — intervention group
Group type: COMPARATOR
Intervention: Unstructured education program (control group)
Number of subjects: 30
Study 7851098 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental condition (helped to apply for SSI)
Number of subjects: 3
Study 7851098 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 3
Study 3288801 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychorelaxation treatment (PRT) using autogenous training, biological feedback, or respiratory relaxation training techniques
Number of subjects: 117
Study 3288801 — intervention group
Group type: COMPARATOR
Intervention: Control group (no psychological effects and psychological placebo)
Number of subjects: 117
Study 31200443 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized MICT + HIIT
Number of subjects: 54
Study 31200443 — intervention group
Group type: COMPARATOR
Intervention: Standardized MICT
Number of subjects: 54
Study 31200443 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study 28463789 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based program
Number of subjects: 48
Study 28463789 — intervention group
Group type: COMPARATOR
Intervention: Pregnancy support program
Number of subjects: 48
Study 25924841 — intervention group
Group type: EXPERIMENTAL
Intervention: Tat 30 μg given 3 times
Number of subjects: 168
Study 25924841 — intervention group
Group type: EXPERIMENTAL
Intervention: Tat 30 μg
Number of subjects: 168
Study 25924841 — intervention group
Group type: EXPERIMENTAL
Intervention: Tat 7.5 μg or 30 μg, given 3 or 5 times monthly
Number of subjects: 168
Study 25924841 — intervention group
Group type: EXPERIMENTAL
Intervention: Tat 30 μg, 3x
Number of subjects: 168
Study 23588194 — intervention group
Group type: EXPERIMENTAL
Intervention: SL‐LVH
Number of subjects: 2993
Study 23588194 — intervention group
Group type: EXPERIMENTAL
Intervention: CV‐LVH
Number of subjects: 2993
Study 23588194 — intervention group
Group type: EXPERIMENTAL
Intervention: CP‐LVH
Number of subjects: 2993
Study 23588194 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP
Number of subjects: 2993
Study 23588194 — intervention group
Group type: EXPERIMENTAL
Intervention: CV‐LVH and CP‐LVH
Number of subjects: 2993
Study 23588194 — intervention group
Group type: EXPERIMENTAL
Intervention: SL‐ECG
Number of subjects: 2993
Study 21311365 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (CR) supplementation (20 g·d(‐1) for 1 week and 5 g·d(‐1) thereafter)
Number of subjects: 0
Study 21311365 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (CR) supplementation
Number of subjects: 0
Study 21311365 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 0
Study 21311365 — intervention group
Group type: COMPARATOR
Intervention: Both CR and PL groups
Number of subjects: 0
Study 19272165 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone group
Number of subjects: 40
Study 19272165 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit group
Number of subjects: 40
Study 19272165 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 17604500 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin analogs
Number of subjects: 0
Study 17604500 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic agents such as IFN‐alpha or cytotoxic chemotherapy
Number of subjects: 0
Study 17604500 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptozocin-based therapy
Number of subjects: 0
Study 17604500 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiolabeled somatostatin analogs
Number of subjects: 0
Study 17604500 — intervention group
Group type: EXPERIMENTAL
Intervention: Agents targeting the VEGF pathway and mammalian target of rapamycin
Number of subjects: 0
Study 15366593 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongluo capsule (TLC)
Number of subjects: 97
Study 15366593 — intervention group
Group type: COMPARATOR
Intervention: Control group (WM group)
Number of subjects: 97
Study 11576034 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine transport in fibroblasts from patients with schizophrenia
Number of subjects: 46
Study 11576034 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 46
Study 9563981 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase (1.5 MU in 1 hour)
Number of subjects: 17187
Study 9563981 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral aspirin (162 mg daily for 1 month)
Number of subjects: 17187
Study 9563981 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of streptokinase and one month of aspirin
Number of subjects: 17187
Study 9563981 — intervention group
Group type: COMPARATOR
Intervention: Matching placebos
Number of subjects: 17187
Study 7981002 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum copper (Cu) and serum copper/zinc ratio (Cu/Zn) in lung cancer patients (LC)
Number of subjects: 162
Study 7981002 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum zinc (Zn) in lung cancer patients (LC)
Number of subjects: 162
Study 7981002 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum copper (Cu) and serum copper/zinc ratio (Cu/Zn)
Number of subjects: 162
Study 7981002 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher Cu and Cu/Zn levels
Number of subjects: 162
Study 7981002 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operator characteristic (ROC) curve for Cu, Cu/Zn, and carcinoembryonic antigen (CEA)
Number of subjects: 162
Study 7981002 — intervention group
Group type: EXPERIMENTAL
Intervention: Determinations of Cu, Zn, and Cu/Zn
Number of subjects: 162
Study 2589003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 2589003 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose
Number of subjects: 26
Study 2589003 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose
Number of subjects: 26
Study 2589003 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter cancellation test
Number of subjects: 26
Study 2589003 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical flicker fusion
Number of subjects: 26
Study 1093559 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine (Kinidin Durules)
Number of subjects: 176
Study 1093559 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 176
Study 31526791 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training by a physical therapist (12 weekly sessions starting at ∼9 weeks postpartum)
Number of subjects: 84
Study 31526791 — intervention group
Group type: COMPARATOR
Intervention: Control group (no instructions after initial assessment)
Number of subjects: 84
Study 31077065 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 75 mg/1 mL solution administered as a 5-s intravenous bolus
Number of subjects: 0
Study 30021506 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered intervention incorporating behavioral activation
Number of subjects: 33